Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 1/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPC1 | O15118 | 3/20 | 0.53 |
| ▸ | RAB9A | P51151 | 3/20 | 0.53 |
| ▸ | MMP12 | P39900 | 3/20 | 0.53 |
| ▸ | MMP2 | P08253 | 2/20 | 0.53 |
| ▸ | MMP1 | P03956 | 1/20 | 0.53 |
| ▸ | MMP9 | P14780 | 1/20 | 0.53 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL260404 | 0.94 | NAAA (0.52) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL12898184 | 0.88 | NAAA (0.54) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL24062797 | 0.86 | NAAA (0.52) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL13684290 | 0.85 | NAAA (0.51) | NAAANPC1RAB9AMMP12MMP2 | |
| SCHEMBL28861927 | 0.83 | NPC1 (0.51) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL5931094 | 0.83 | EGFR (0.55) | ALDH1A1MAPT | |
| SCHEMBL6646548 | 0.83 | AGXT (0.52) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL26555 | 0.83 | AGXT (0.52) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL2299547 | 0.82 | NAAA (0.49) | NAAAALDH1A1NPC1RAB9AMMP12 | |
| SCHEMBL25509839 | 0.82 | NPC1 (0.51) | NAAAALDH1A1NPC1RAB9AMMP12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190497-A1 | Process for production of 2,5 dioxopyrrolidine 3 carboxylate | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190497-A1 | Process for production of 2,5 dioxopyrrolidine 3 carboxylate | REN, PKD1, KCNT1 | NAAA 881/4885ALDH1A1 423/4885NPC1 2782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.